Pfizer Inc. (NYSE:PFE) Stock Has Average Price Target of $28.72 According to Brokerages

Pfizer Inc. (NYSE:PFE) has received an average rating of “Hold” from the twenty-one analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $28.72.

A number of analysts have recently issued reports on the stock. BMO Capital Markets dropped their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Scotiabank lifted their target price on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. HSBC boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th.

Pfizer Stock Performance

NYSE:PFE opened at $29.88 on Thursday. The firm’s 50 day moving average is $28.19 and its two-hundred day moving average is $26.59. The company has a market cap of $170.28 billion, a P/E ratio of 39.31, a P/E/G ratio of 2.04 and a beta of 0.32. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer has a fifty-two week low of $23.62 and a fifty-two week high of $30.25.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the business earned $0.78 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. boosted its holdings in Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after purchasing an additional 745,213 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Pfizer by 10.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after buying an additional 232,528 shares during the last quarter. Leuthold Group LLC acquired a new stake in shares of Pfizer in the second quarter worth $4,887,000. Park National Corp OH grew its position in Pfizer by 332.1% in the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 186,053 shares during the last quarter. Finally, 111 Capital acquired a new stake in Pfizer during the second quarter worth about $3,706,000. 68.36% of the stock is currently owned by institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares recently outperformed the broader market in a trading session, reflecting renewed investor interest in pharmaceutical stocks as technology shares weakened. The stock is also trading near its one-year high and above its 50-day and 200-day moving averages, indicating improved momentum. Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
• Positive Sentiment: Investor confidence has been supported by Pfizer’s 2026 oncology progress, including breast-cancer approvals and a multibillion-dollar cancer alliance. Pfizer also generated a positive year-to-date total return, including dividends, reinforcing the case that its pipeline transition may be gaining credibility. What Pfizer Bulls Got Right
• Positive Sentiment: Pfizer’s approximately 5.8% dividend yield remains a central attraction for income investors. Its latest reported quarter also exceeded analyst expectations for earnings and revenue, while management’s fiscal 2026 earnings guidance provides a framework for valuation. What Have Pfizer Stock Holders Really Earned?
• Neutral Sentiment: Pfizer disclosed an ongoing study evaluating exposure to etrasimod in breastfeeding women. The update may support future labeling and commercial planning, but it does not provide efficacy or approval results that would immediately change the investment outlook. Pfizer’s Etrasimod Breastfeeding Study
• Negative Sentiment: Despite the dividend, Pfizer’s share-price performance over the past five years has lagged the S&P 500. That history, along with a relatively elevated earnings multiple and sharply lower recent net margins, may limit enthusiasm among growth-oriented investors. What Have Pfizer Stock Holders Really Earned?

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.